Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 5, 2013

Primary Completion Date

August 31, 2016

Study Completion Date

May 4, 2017

Conditions
Extensive-Stage Small-Cell Lung Cancer
Interventions
DRUG

Carfilzomib

Administered by intravenous infusion.

DRUG

Carboplatin

Administered by intravenous infusion.

DRUG

Etoposide

Administered by intravenous infusion.

Trial Locations (17)

Unknown

Yale University, Yale Cancer Center, New Haven

UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville

Goshen Center for Cancer Care, Goshen

Horizon Oncology Research, Inc., Lafayette

Indiana University Health Ball Memorial Hospital, Muncie

Baptist Health Lexington Clinical Research Center, Lexington

Frederick Memorial Hospital, Frederick

John Theurer Cancer Center at Hackensack UMC, Hackensack

Levine Cancer Institute, Charlotte

Wake Forest Baptist Health, Winston-Salem

The University of Texas MD Anderson Cancer Center, Houston

Juravinski Cancer Centre, Hamilton

"Regional Budgetary Healthcare Institution Kursk Regional Clinical Oncology Dispensary", Kislino

"State budgetary healthcare institution of Arkhangelsk Region Arkhangelsk Clinical Oncological Dispensary", Arkhangelsk

"Federal State Budgetary Scientific Institution N.N. Blokhin Russian Cancer Research Center", Moscow

"State Budgetary Educational Inslitution of Higher Professional Education First St. Petersburg I.P.Pavlov State Medical University", Saint Petersburg

"State Budgetary Healthcare Institution of Yaroslavl Region Regional Clinical Oncological Hospital", Yaroslavl

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01987232 - Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer | Biotech Hunter | Biotech Hunter